



Regd. Office:

'Zydus Tower', Satellite Cross Roads, Ahmedabad 380 015. India. Phone: +91-79-2686 8100 (20 Lines)

Fax : +91-79-2686 2368 www.zyduscadila.com CIN:L24230GJ1995PLC025878

BSE Limited

1st Floor, P.J. Towers

Dalal Street

Mumbai - 400 001

Kind Attn.:

Mr. Sanjay Golecha /

Mr. Gopalkrishnan

National Stock Exchange of India Limited

Exchange Plaza, 5th Floor,

Plot No. C/1, G Block, Bandra-Kurla Complex, Bandra (East)

Mumbai - 400 051

Kind Attn.:

Famroze Pochara

Asst. Vice President

Date:

June 21, 2017

Re.:

Press Release

Dear Sir / Madam,

We enclose herewith a copy of press release dated June 21, 2017, titled Zydus receives EIR Report for Moraiya Manufacturing Facility.

The contents of the press release give full details.

Please bring the aforesaid news to the notice of the members of the exchange and the investors' at large.

Thanking you,

Yours faithfully,

For, Cadila Healthcare Limited

Upen H. Shah

Company Secretary

Encl.: As above



Press Release

Press Lelease

Zydus receives EIR Report for Moraiya Manufacturing Facility

Produce Nelease

Ahmedabad 21, June 2017

Zydus Cadila's formulations manufacturing facility at Moraiya, Ahmedabad has received an Establishment Inspection Report (EIR) from the USFDA signifying the successful closure of the audit. The Moraiya manufacturing plant had completed the USFDA audit from February 6th to 15th 2017 with Zero 483 observations. Post the audit, the plant has received several product approvals, including the final approval to market Mesalamine Delayed-Release Tablets USP, 1.2 g in the US.

About Zydus Cadila

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group employs over 20000 people worldwide and is dedicated to creating healthier communities globally. Zydus aspires to be a research-based pharmaceutical company by 2020.
